Related Experiment Videos
Has multivessel angioplasty displaced surgical revascularization?
Insights
Percutaneous transluminal coronary angioplasty (PTCA) is effective for single-vessel coronary artery disease (CAD). While advancements facilitate its use in multivessel CAD, surgery remains crucial for certain conditions, pending further trial results.
Area of Science:
- Cardiology
- Interventional Cardiology
- Vascular Surgery
Background:
- Percutaneous transluminal coronary angioplasty (PTCA) is established as a safe and effective treatment for single-vessel coronary artery disease (CAD).
- Technological advancements in balloon, guidewire, and guide catheter technology have enabled the expansion of PTCA to treat multivessel CAD.
- Established guidelines aid in selecting appropriate cases for PTCA, though its role relative to surgery is still evolving.
Purpose of the Study:
- To review the current status and evolving role of PTCA in managing coronary artery disease, particularly multivessel CAD.
- To compare the efficacy and indications of PTCA versus coronary artery bypass grafting (CABG) for different CAD presentations.
- To discuss the impact of technological advancements and ongoing research on treatment strategies.
Main Methods:
- Review of historical data and clinical outcomes of PTCA for single and multivessel CAD.
- Analysis of technological developments facilitating PTCA procedures.
- Discussion of current guidelines and the necessity of surgical standby for PTCA.
- Consideration of ongoing randomized trials comparing PTCA and CABG.
Main Results:
- PTCA demonstrates satisfactory success rates and acceptable complication rates for multivessel CAD, supported by technological progress.
- Surgical intervention remains the preferred treatment for left main coronary artery disease and may be necessary for complex multivessel disease.
- Emergency surgical backup is essential for managing potential complications during PTCA procedures.
- The long-term efficacy, cost-effectiveness, and event limitation of PTCA versus CABG are under investigation in ongoing trials.
Conclusions:
- PTCA is a valuable therapeutic option for CAD, increasingly applied to multivessel disease due to technological advancements.
- Despite PTCA's success, coronary artery bypass grafting (CABG) retains its primary role in specific complex cases, such as left main disease.
- Further evidence from randomized trials is required to definitively establish the optimal revascularization strategy for multivessel CAD regarding long-term survival and outcomes.
Abstract:
Over the years, PTCA has been proved a safe and effective therapy for single-vessel CAD. Given the record of favorable results for single-vessel angioplasty, the extension of angioplasty to multivessel CAD soon followed. The successful application of PTCA to multivessel disease has been facilitated by developments in balloon, guidewire, and guide catheter technology. Success rates have been satisfactory, and complications have remained acceptable. Furthermore, as an outgrowth of an understanding of the mechanism and effect of PTCA, guidelines have been developed to aid case selection. As emphasized earlier, these guidelines should weigh heavily in deciding whether to select PTCA as a treatment modality. Presently, in our opinion, PTCA has not yet completely displaced surgery for multivessel CAD. Surgical standby is required for safe PTCA, because emergency surgery can be lifesaving and limit myocardial infarction after failed angioplasty. It is doubtful that surgery will ever relinquish its position as the treatment of choice for left main coronary artery disease. Nor will elective surgery find wide application in single-vessel disease. Whether one mode of revascularization will emerge as the most efficacious for multivessel disease related to long-term survival, limitation of cardiac events, and cost will be addressed in the analysis of the ongoing randomized trials of surgery versus angioplasty. Andreas Gruentzig established that it was possible to work within the coronary artery in an alert and comfortable patient. Interventional cardiology has experienced rapid technologic growth. Many patients formerly treated with bypass surgery can be managed effectively with angioplasty. If effective bail-out methods for acute closure are proven effective and restenosis is limited to a small percentage of patients, angioplasty in some form will further displace CABG. Until those ultimate goals are achieved, the value of angioplasty compared with bypass surgery must rest with current local experience and the eagerly awaited results of randomized trials.